Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lymphoma, B-Cell Clinical Trials

A listing of Lymphoma, B-Cell medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (598) clinical trials

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

The study will be done in two phases namely phase 1B and phase 2. In the phase 1B component the investigators intend to enroll patients in a 3+3 dose escalation design. Newly diagnosed indolent and diffuse large cell lymphomas as well as relapsed/refractory indolent B cell lymphomas are eligible for ...

Phase

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

PRIMARY OBJECTIVES: I. To reduce the incidence of relapse at 18 months after reduced-intensity conditioning (RIC) and allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) in blast crisis from a historical baseline of 45% to 25%, using ibrutinib maintenance ...

Phase

Identification of Occupational Exposures in Acute Hematologic Malignancy

This study is a prospective, multicenter study on patients with a diagnosis of NHL, MM or CLL. All the patients with a diagnosis of NHL, MM or CLL in the participant centers will be purposed to participate. Each patient included will have an interview with a clinical study technician or ...

Phase N/A

Study of Acalabrutinib Alone or in Combination With Rituximab in Indolent B-cell Non-Hodgkin Lymphoma

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent B cell Non-Hodgkin Lymphoma - Marginal Zone Lymphoma

Phase

Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Study Drug Administration: Each study cycle is 6 weeks. If you are found to be eligible to take part in this study, you will receive blinatumomab by a central venous catheter (CVC) continuously for Weeks 1-4 of each cycle. A CVC is a sterile flexible tube that will be placed ...

Phase

BNHL-2015 for Children or Adolescents in China

In our previous study (CCCG-NHL-2010), two-year EFS was 100% for Stage I, 91.3% 6.1% for Stage II, 75.8% 4.4% for Stage III, 56.3% 13.5% for Stage IV, and 36.4% 14.5% for B-AL, respectively. To improve survival for pediatric patients with B-NHL/B-AL, the investigators launched a new study in China. Compared ...

Phase

A Phase I Study of AC0010 in Patients With CLL/ SLL MCL DLBCL and Other NHL

This is an open label, dose escalation, phase I study to determine the PR2D by assessing the DLT, safety and efficacy of AC0010 in patients with B-cell lymphoma. This study includes two parts. During Part 1 Dose Escalation, the "3+3" design will be applied. Dose escalation will begin at dose ...

Phase

Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis

In this study, the investigators will utilize a regimen combining low dose total body irradiation and rabbit ATG to facilitate stem cell transplantation (SCT) with HLA matched related and unrelated donors. Based on the hypothesis that early treatment interventions have significant late effects in allogeneic SCT, a simple intervention, varying ...

Phase

Carfilzomib Rituximab Ifosfamide Carboplatin and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and examine the dose-limiting toxicities of carfilzomib when administered in combination with rituximab, ifosfamide, carboplatin, and etoposide (C-R-ICE) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). (Phase I) II. To assess the toxicity of dose regimen using the Cancer ...

Phase

A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas

This will be a First-in-Human, Phase 1, multi-center, non-randomized, open label study of DS-3201b, Histone-lysine N-methyltransferase EZH1/2 dual inhibitor to assess its safety and tolerability, identify a maximum tolerated dose (MTD)/ tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic/dynamic properties in Japanese subjects with Non-Hodgkin's Lymphoma.

Phase